Maria Liljefors

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: THE LANCET GASTROENTEROLOGY AND HEPATOLOGY. 2024;9(3):205-217
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Labori KJ; Bratlie SO; Andersson B; Angelsen J-H; Biorserud C; Bjornsson B; Bringeland EA; Elander N; Garresori H; Gronbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TA; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandstrom P; Sparrelid E; Stenvold H; Soreide K; Tingstedt B; Verbeke C; Ohlund D; Klint L; Dueland S; Lassen K
Article: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7196-7205
Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study
Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Article: BMC CANCER. 2023;23(1):949
Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer
Crespo-Bravo M; Thorlacius-Ussing J; Nissen NI; Pedersen RS; Boisen MK; Liljefors M; Johansen AZ; Johansen JS; Karsdal MA; Willumsen N
Article: WORLD JOURNAL OF SURGICAL ONCOLOGY. 2023;21(1):286
Gallbladder cancer mimicking perihilar cholangiocarcinoma-considerable rate of postoperative reclassification with implications for prognosis
Nooijen LE; Gustafsson-Liljefors M; Erdmann JI; D'Souza MA; Gilg S; Villard C; Jansson H
Article: ANNALS OF SURGICAL ONCOLOGY. 2023;30(7):4433-4441
Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study
Graversen M; Rouvelas I; Ainsworth AP; Bjarnesen AP; Detlefsen S; Ellebaek SB; Fristrup CW; Liljefors MG; Lundell L; Nilsson M; Pfeiffer P; Tarpgaard LS; Tsekrekos A; Mortensen MB
Article: PANCREATOLOGY. 2022;22(5):598-607
Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma
Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Lohr J-M; Sparrelid E
Article: SCIENTIFIC REPORTS. 2021;11(1):865
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Nissen NI; Kehlet S; Boisen MK; Liljefors M; Jensen C; Johansen AZ; Johansen JS; Erler JT; Karsdal M; Mortensen JH; Hoye A; Willumsen N
Article: CANCERS. 2019;11(9):E1326-1326
Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
Kordes M; Yu J; Malgerud O; Liljefors MG; Lohr J-M
Article: MOLECULAR ONCOLOGY. 2017;11(10):1413-1429
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Gronberg H; Lohr J-M
Article: PLOS ONE. 2017;12(1):e0169736
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Ullenhag GJ; Mozaffari F; Broberg M; Mellstedt H; Liljefors M
Article: PLOS ONE. 2015;10(4):e0121197
A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Ullenhag GJ; Rossmann E; Liljefors M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Staff C; Mozaffari F; Frodin J-E; Mellstedt H; Liljefors M
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frodin J-E; Wahren B; Mellstedt H; Ullenhag GJ
Article: VACCINE. 2011;29(39):6817-6822
A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients
Staff C; Mozaffari F; Haller BK; Wahren B; Liljefors M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(6):1599-1606
FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment
Wang B; Kokhaei P; Mellstedt H; Liljefors M
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2008;130(3):375-381
Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis
Rubio CA; Orrego A; Hoog A; Porwitz A; F'etersson F; Elmberger G; Glaessgen A; Eriksson E; Kanter L; Jaremko G; Egevad L; Laforga J; Liljefors M; Lofdahl B; Norman P; Larsson O; Wanat R; Wejde J; Zickert P; Bjork J; Caini S; Palli D; Nesi G
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(3):379-388
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity
Liljefors M; Nilsson B; Mellstedt H; Mellstedt H; Frodin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with α-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383
Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients
Shetye JD; Liljefors ML; Emdin SO; Frödin JE; Strigård K; Mellstedt HT; Porwit A
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723
Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
Liljefors M; Nilsson B; Skog ALH; Ragnhammar P; Mellstedt H; Frödin JE
Article: HYBRIDOMA. 2002;21(2):99-101
MAb17-1A and Cytokines for the treatment of patients with colorectal carcinoma
Frödin JE; Fagerberg J; Skog ALH; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1999;48(8):463-470
Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma
Skog ALH; Ragnhammar P; Fagerberg J; Frödin JE; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1999;5(6):1353-1361
Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF
Wadhwa M; Skog ALH; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929
Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frodin JE; Biberfeld P; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1996;42(2):81-87
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frodin JE
Visa fler

Alla övriga publikationer

Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7257-7258
ASO Visual Abstract: Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study
Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(12):7251-7252
ASO Author Reflections: The Impact of Minimally Invasive Surgery on the Completion Rate of the Perioperative Chemotherapy Protocol in Gastric Cancer
Tsekrekos A; Borg D; Johansson V; Nilsson M; Klevebro F; Lundell L; Gustafsson-Liljefors M; Rouvelas I
Editorial comment: ANNALS OF SURGICAL ONCOLOGY. 2023;30(7):4442-4443
ASO Visual Abstract: Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence: The PIPAC-OPC4 Study
Graversen M; Rouvelas I; Ainsworth AP; Bjarnesen AP; Detlefsen S; Ellebaek SB; Fristrup CW; Liljefors MG; Lundell L; Nilsson M; Pfeiffer P; Tarpgaard LS; Tsekrekos A; Mortensen MB
Editorial comment: JCO PRECISION ONCOLOGY. 2021;5:974-980
Discordant Reporting of a Previously CD Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma
Kordes M; Tamborero D; Lagerstedt-Robinson K; Yachnin J; Rosenquist R; Lohr J-M; Liljefors MG
Meeting abstract: ANNALS OF ONCOLOGY. 2018;29:vi31
Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001
Kordes M; Lohr M; Malgerud L; Kaduthanam S; Frodin J-E; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel R; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Engstrand L; Brock S; Gustafsson-Liljefors M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16243
Palliative treatment of pancreatic adenocarcinoma in a real-world setting.
Kordes M; Malgerud O; Karimi M; Frodin J-E; Liljefors MG; Loehr M
Thesis / dissertation: 2012
Immunotherapy with the anti-EpCAM monoclonal antibody and cytokines in patients with colorectal cancer : a clinical and experimental study
Gustafsson Liljefors, Maria
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A

Anställningar

Anknuten till Forskning, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2022-2024

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2017
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2005
Läkarexamen, Karolinska Institutet, 1992

Handledare

Cecilia Merk, 2022

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Handledare

Nyheter från KI

Kalenderhändelser från KI